Cargando…

The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by well-defined neuropathological brain changes including amyloid plaques, neurofibrillary tangles and the presence of chronic neuroinflammation. Objective: The brain penetrant BET bromodomain inhibitor JQ1 has been sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magistri, Marco, Velmeshev, Dmitry, Makhmutova, Madina, Patel, Prutha, Sartor, Gregory C., Volmar, Claude-Henry, Wahlestedt, Claes, Faghihi, Mohammad Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026248/ https://www.ncbi.nlm.nih.gov/pubmed/27117003 http://dx.doi.org/10.2174/1567205013666160427101832

Ejemplares similares

Transcriptomics Profiling of Alzheimer’s Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, and Deregulated Expression of Long Noncoding RNAs
por: Magistri, Marco, et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research
por: Dennison, Jessica L., et al.
Publicado: (2021)

Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse
por: Dennison, Jessica, et al.
Publicado: (2023)

Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model
por: Janczura, Karolina J., et al.
Publicado: (2018)

A novel knockout mouse model of the noncoding antisense Brain-Derived Neurotrophic Factor (Bdnf) gene displays increased endogenous Bdnf protein and improved memory function following exercise
por: Modarresi, Farzaneh, et al.
Publicado: (2021)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
por: Yamamoto, Keisuke, et al.
Publicado: (2016)

BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis
por: Wang, Xiaorong, et al.
Publicado: (2021)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells
por: Kato, Fuyumi, et al.
Publicado: (2016)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
por: Chan, Kwok-Ho, et al.
Publicado: (2017)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
por: Bauer, Karin, et al.
Publicado: (2018)

Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production
por: Gibbons, Hunter R., et al.
Publicado: (2019)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
por: Bian, Benjamin, et al.
Publicado: (2017)

Expression of non-protein-coding antisense RNAs in genomic regions related to autism spectrum disorders
por: Velmeshev, Dmitry, et al.
Publicado: (2013)

Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment
por: Marchesi, Irene, et al.
Publicado: (2022)

Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice
por: Chen, Yanxing, et al.
Publicado: (2014)

CANEapp: a user-friendly application for automated next generation transcriptomic data analysis
por: Velmeshev, Dmitry, et al.
Publicado: (2016)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

Olfactory dysfunction in the 3xTg-AD model of Alzheimer’s disease
por: Mitrano, Darlene A., et al.
Publicado: (2021)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1
por: Orekhova, Anastasia, et al.
Publicado: (2022)

Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice
por: Van der Jeugd, Ann, et al.
Publicado: (2018)

Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1
por: Lv, Baojie, et al.
Publicado: (2018)

The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines
por: Lines, Kate E, et al.
Publicado: (2021)

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors
por: Veneziani, Irene, et al.
Publicado: (2019)

Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer’s disease
por: Gloria, Yesica, et al.
Publicado: (2021)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
por: Fujiwara, Hiroaki, et al.
Publicado: (2018)

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells
por: Garcia, Patrick L., et al.
Publicado: (2022)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_m4j17n2vp9nd9t3llce60nqhqv